Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson
Harvard Business School

Last Updated: December 11, 2019

DrugPatentWatch Database Preview

Litigation Details for Apotex Inc. v. Daiichi Sankyo, Inc. (N.D. Ill. 2012)

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Apotex Inc. v. Daiichi Sankyo, Inc. (N.D. Ill. 2012)

Docket   Start Trial Date Filed 2012-11-20
Court District Court, N.D. Illinois Date Terminated 2016-01-08
Cause 28:2201 Declaratory Judgement Assigned To Sharon Johnson Coleman
Jury Demand None Referred To
Patents 5,616,599; 6,878,703
Attorneys Autumn N. Nero; C. Austin Ginnings; David C. Van Dyke; David Joseph Piech; David L. Anstaett; David R. Pekarek Krohn; Dennis D. Gregory; Dominick A Conde; Emily Elizabeth Bennett; Emily J. Greb; James B Coughlan; James Patrick White; Jay P. Lefkowitz; John k. Crisham; Joseph W. Barber; Joshua Calabro; Leonard Friedman; Lisa Barons Pensabene; Michael D. Shumsky; Nina Shreve; Sarah P. Herlihy; Shannon M. Bloodworth; Sherry Lee Rollo; Steven Eric Feldman; Steven Menashi
Firms Fitzpatrick, Cella, Harper & Scinto; Hahn Loeser & Parks LLP; Howard & Howard; Howard & Howard Attorneys PC; Howard & Howard Attorneys PLLC; Husch Blackwell Sanders Welsh & Katz; Kirkland & Ellis LLP; Kirkland & Ellis, LLP; Perkins Coie LLP
Link to Docket External link to docket
Small Molecule Drugs cited in Apotex Inc. v. Daiichi Sankyo, Inc.
The small molecule drugs covered by the patents cited in this case are   Start Trial ,   Start Trial ,   Start Trial , and   Start Trial .

Details for Apotex Inc. v. Daiichi Sankyo, Inc. (N.D. Ill. 2012)

Date Filed Document No. Description Snippet Link To Document
2016-01-08 135 United States Patents Nos. 6,878,703 (the “703 patent”) and 5,616,599 (the “599 patent”) with the FDA…1) no patent information has been filed with the FDA, (2) the patent has expired, (3) the patent will …infringed the ‘599 patent, and Mylan’s Paragraph IV certifications for that patent were thus converted…ANDA infringed on a patent, and that it should not be considered until that patent expired). Mylan’s ANDAs…Paragraph IV certifications as to the ‘703 patent because that patent, although disclaimed, remains listed External link to document
2014-01-09 49 United States Patents Nos. 6,878,703 (the “‘703 Patent”) and 5,616,599 (the “‘599 Patent”) in connection… no patent information has been filed with the FDA; (II) the patent has expired; (III) the patent will…both Patents ‘703 and ‘599, Daiichi sued Mylan on July 31, 2006 for infringement of the ‘599 patent in …regarding the ‘599 patent, Daiichi statutorily disclaimed every claim of the ‘703 patent pursuant to 35 U.S.C…court found that the ‘599 patent was valid and that Mylan infringed the ‘599 patent. Mylan never brought a External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.